Eurotrol Presents the Future of Blood Gas Controls at MEDICA 2022
|
By LabMedica International staff writers Posted on 16 Nov 2022 |

Eurotrol, Inc. (Elizabethtown, KY, USA) is demonstrating its innovative, patented packaging concept that will modernize the in vitro diagnostic market at MEDICA 2022 Trade Fair being held in Düsseldorf, Germany from 14-17th November.
Eurotrol’s CueSee Ringe is being touted as the future of blood gas controls. A special glass ampoule is sealed inside the CueSee Ringe device. This ampoule breaks with a simple turning motion without the risk of cutting fingers on glass particles or coming into contact with the liquid. After this activation step, the CueSee Ringe functions identically to a standard syringe. The liquid inside the ampoule is not deteriorated by environmental contamination, which reduces pre-analytical errors. This concept is ideal for solutions typically stored in ampoules for quality control, calibration verification, proficiency testing, competency assessment, method validations, and lot comparisons.
At MEDICA 2022, Eurotrol is also demonstrating a breakthrough product, the CueSee CO-OX. Co-oximetry determines the levels of the various derivatives of hemoglobin (Hb) in a patient’s blood. Being able to accurately detect and measure the amount of oxyhemoglobin available to carry O2 to the cells of the body is essential, as well as measurements of the abnormal Hb derivatives: carboxyhemoglobin and methemoglobin. It is crucial that co-oximetry testing for these fractions are validated and proven to measure all, at normal and abnormal levels. CueSee CO-OX has proven performance to help meet everyone’s needs. Eurotrol has revolutionized quality control for CO-oximeters by developing CueSee CO-OX with real hemoglobin derivatives performing like patient samples. Packaged in the ACU-Drop II, this dual-chambered device keeps the oxyhemoglobin separated from the methemoglobin to provide a long shelf-life.
Related Links:
Eurotrol, Inc.
Latest MEDICA 2022 News
- Bosch Demonstrates Vivalytic All-In-One PCR Analyzer at MEDICA 2022
- Biovendor Group Presents CLIA Solution for Complex Diagnostics at MEDICA 2022
- Diatron Exhibits Advanced Hematology and Clinical Chemistry Analyzers at MEDICA 2022
- Immundiagnostik AG Presents New PCR Test MutaPLEX RespiraScreen4_Diff_seqc at MEDICA 2022
- Rhinomed Announces European Launch of Revolutionary New Swab for Testing Children for Respiratory Diseases

- Absology Exhibits POCT Immunoassay Analyzer with Testing Time of Five Minutes
- Cormay Diagnostics Introduces True 5+ DIFF Multi-Patented Hematology Solution at MEDICA 2022
- EDAN Takes its Solutions up a Notch at MEDICA 2022
- Bioneer Presents Near-Patient POC Molecular Diagnostic System at MEDICA 2022
- Rhinostics Features New RHINObot Automated Decapper at MEDICA 2022
- MP Biomedicals Exhibits Innovative POC, Screening and Confirmatory Tests at MEDICA 2022
- Oxford Immunotec Showcases Automated T-SPOT.TB Test at MEDICA 2022
- Boditech Highlights Automated Benchtop and Handheld Immunoassay Readers at MEDICA 2022
- Co-Diagnostics Introduces its CoPrimer Technology and Applications at MEDICA 2022
- Sentinel Diagnostics Presents New Fully Automated Sample to Result System for Diagnosis of Viral Infections
- Serosep Exhibits EntericBio System for Testing, Detecting and Identifying GI Pathogens at MEDICA 2022
Channels
Clinical Chemistry
view channel
Updated PSA Testing Guidelines Support Early Prostate Cancer Detection
Prostate cancer is the second leading cause of cancer-related death among men in the United States, with an estimated 333,830 new cases and 36,320 deaths this year, according to the American Cancer Society.... Read more
Antibody-Free Blood Test Detects Rheumatic Heart Disease Biomarker
Rheumatic heart disease (RHD) causes hundreds of thousands of deaths annually, disproportionately affecting children and young adults in low- and middle-income countries. Early detection remains challenging... Read moreMolecular Diagnostics
view channel
AI in Cancer Diagnosis and Molecular Testing Takes Center Stage at AMP 2026
Artificial intelligence (AI) is increasingly being integrated into molecular diagnostics, offering new approaches to interpreting complex genetic information, classifying cancers, and optimizing laboratory testing.... Read more
AMP 2026 Highlights Advances in Molecular Testing for Pediatric Diseases
Advances in molecular diagnostics are creating new opportunities to identify inherited diseases earlier, improve the classification of childhood cancers, and track infectious disease outbreaks affecting children.... Read more
Genomic Studies Investigate Treatment Response and Inherited Risk in Sarcoma
Tempus AI (Chicago, IL, USA) will present six abstracts, including three oral presentations, at the Connective Tissue Oncology Society (CTOS) 2026 Annual Meeting, taking place November 18–21 in Seoul, South Korea.... Read moreHematology
view channel
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read more
Study Confirms Blood Products Remain Viable After Three Weeks in the Arctic
Trauma and hemorrhage care in Canada’s High Arctic is complicated by long evacuation times, extreme temperatures, and limited access to blood products. In remote military and northern communities, reaching... Read moreImmunology
view channel
Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis
Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more
Antibody Testing Informs Melioidosis Diagnosis and Surveillance in Emerging Regions
Melioidosis is a serious and sometimes fatal infection caused by the soil- and water-dwelling bacterium Burkholderia pseudomallei. People and animals can contract the disease through exposure to contaminated... Read moreMicrobiology
view channel
Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum
Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more
Automated Microbial Identification and Susceptibility System Gains FDA Clearance
Antimicrobial resistance (AMR) is a leading global public health threat, causing an estimated 1.27 million deaths annually. The growing challenge of diagnosing and treating resistant infections highlights... Read more
Gastrointestinal Flex Assay Gains EU Certification for Tailored Pathogen Testing
Gastrointestinal infections can be caused by bacterial, viral, or parasitic pathogens, making targeted test selection important for clinical laboratories. Fixed syndromic panels may be broader than necessary... Read more
Molecular Panels Gain FDA Clearance for One-Hour Gastrointestinal Pathogen Testing
Acute infectious gastroenteritis, caused by viral, bacterial, and parasitic pathogens, remains a significant global health concern that inflames the gastrointestinal tract. Symptoms such as diarrhea, vomiting,... Read morePathology
view channel
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more
Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
Oral cavity and oropharyngeal cancers remain a significant diagnostic challenge, with more than 60,000 Americans expected to be diagnosed in 2026 and more than 13,000 expected to die from these cancers.... Read more
AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
In early-stage breast cancer, precision oncology relies on biological information to guide personalized treatment decisions. Because access to tissue-based genomic testing may be limited, there is growing... Read moreTechnology
view channel
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read more
Multi-Agent AI Framework Supports Laboratory Quality and Workflow Monitoring
Clinical laboratories analyze blood, urine, tissue, and other bodily fluids to support disease diagnosis and treatment. Rising test volumes, workforce shortages, and increasingly complex diagnostics are... Read moreIndustry
view channel
Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study
Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Partnership Aims to Bring Blood-Based Alzheimer’s Testing to Japan
Alzheimer’s disease remains a growing diagnostic challenge as populations age and cognitive impairment becomes more common. In Japan, government-supported estimates project that approximately 4.... Read more








